News List

Navitas Life Sciences to consolidate capabilities of Ecron Acunova, Navitas, Intelent brands


Ecron Acunova will consolidate its capabilities with TAKE’s Life Sciences brand Navitas and Intelent to form a unified go-to-market entity — Navitas Life Sciences.

By Team ABLE

Ecron Acunova (EA), a fully owned subsidiary of Chennai-based TAKE Solutions and a globally recognized full service CRO with Clinical and BA/BE expertise, has announced that it would be consolidating its capabilities with TAKE’s Life Sciences brand Navitas and Intelent to form a unified go-to-market entity — Navitas Life Sciences.

EA’s clinical capabilities, having conducted over 1300 studies including BA/BE, NIS, and phase II – IV in its facilities, will be augmented by Navitas’s technology led solutions across Clinical, Regulatory and Safety, and Intelent’s big data and analytics expertise to form the 360-degree service provider Navitas Life Sciences. 

The company’s release says that the unified Navitas Life Sciences will serve as an end-to-end strategic partner for Life Sciences companies to help them address their critical challenges and achieve their desired outcomes.

Marty Boom, Managing Director, Ecron Acunova, said, “Capitalizing on the phenomenal growth opportunities in the Life Sciences industry calls for diverse capabilities. The unification of Ecron Acunova, Navitas and Intelent will enable a seamless consolidation of capabilities in the form of Navitas Life Sciences, which will enable us to offer clients a full-service coverage of the Pharma and Biotech R&D market.”

Ram Yeleswarapu, President & CEO, TAKE Solutions, said, “We are proud to bring together our substantial and niche capabilities under the unified ambit of Navitas Life Sciences to present our client with truly transformational, flexible and adaptable end-to-end offerings. In addition to our technology driven offerings and insights derived from our world-class proprietary industry networks, our clients now also be able to benefit from the consolidated brand’s proven clinical capabilities and trial experiences.”